

Latin America Respiratory Inhalers Market Report and Forecast 2024-2032

Market Report | 2024-06-26 | 140 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$3999.00
- Five User License \$5299.00
- Corporate License \$6299.00

Report description:

Latin America Respiratory Inhalers Market Report and Forecast 2024-2032

Latin America Respiratory Inhalers Market Size

The global respiratory inhalers market was valued at USD 33.5 billion in 2023, with Latin America holding a significant market share. The market is driven by the rising incidence of chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). It is expected to grow at a CAGR of 5.4% during the forecast period of 2024-2032, with the values likely to attain USD 53.9 billion by 2032.

Latin America Respiratory Inhalers Market Outlook

- Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory condition in the Latin American region, particularly in men, smokers and ex-smokers. The rising burden of respiratory diseases is expected to directly impact the market demand. One of the major Latin America respiratory inhalers market trends is the growing focus on the development of eco-friendly respiratory inhaler products. In April 2024, Mundipharma and Vectura announced plans to incorporate an environmentally friendly propellant into the reformulation of flutiform used in a pressurized metered-dose inhaler (pMDI) to reduce the product's carbon footprint.
- The growing adoption of technologically advanced inhaler devices such as digital inhalers that offer additional features such as tracking medication usage and dosage are likely to boost the market share.

Latin America Respiratory Inhalers Market Analysis

Respiratory inhalers are medical devices that are designed to provide quick relief from respiratory symptoms or deliver medication to manage chronic respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Metered-dose inhalers are the most common type of inhalers that use a propellant to spray out the medication in a short burst. There is an increasing use of technologically advanced inhaler devices such as digital inhalers that offer additional features such as tracking medication usage and dosage. The rising adoption of such innovative inhaler solutions to monitor patient compliance

Scotts International, EU Vat number: PL 6772247784

and adherence is expected to propel the Latin America respiratory inhalers market growth.

In Latin America, the increasing burden of respiratory diseases is directly impacting the market dynamics. Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory condition in the Latin American region, particularly in men and in smokers and ex-smokers, which drives the demand for advanced respiratory inhalers. Further, in April 2023, a study reported that the healthcare costs associated with exacerbation of COPD are very high in Brazil, reaching an amount of nearly USD 14,657 per hospitalization. This indicates the need for effective respiratory care products including inhalers to prevent the worsening of COPD symptoms and ensure consistent and proper dosing of medications, which is likely to augment the Latin America respiratory inhalers market demand.

One of the major market trends is the growing focus on the development of sustainable healthcare solutions including the development of eco-friendly respiratory inhaler products. For instance, in April 2024, global healthcare company Mundipharma and specialist inhalation contract development and manufacturing organization Vectura announced plans to incorporate an environmentally friendly propellant into the reformulation of flutiform (indicated in the regular treatment of asthma) used in a pressurized metered-dose inhaler (pMDI) with the aim of reducing the product's carbon footprint. Such substantial investment in the advancement of respiratory inhalers with a lower environmental impact is anticipated to elevate the market value in the forecast period.

Latin America Respiratory Inhalers Market Segmentation??

The report offers a detailed analysis of the market based on the following segments:

Market Breakup by Product Type

- Dry Powdered Inhalers
- o

 Multi-Dose Dry Powder Inhalers
- o
 Single Dose Dry Powder Inhalers
- Metered Dose Inhalers
- o
 || Pressured Metered Dose Inhalers
- o
 Connected Metered Dose Inhalers
- o

 ☐Compressed Air Nebulizers
- o∏Mesh Air Nebulizers
- o

 Ultrasonic Air Nebulizers

Market Breakup by Technology

- -∏Manually Operated Inhaler
- Digitally Operated Inhaler

Market Breakup by Indication

- -∏Asthma
- -□COPD
- Pulmonary Arterial Hypertension
- -□Other Respiratory Diseases

Market Breakup by Distribution Channel

- -□Hospital Pharmacies
- -□Retail Pharmacies
- -∏Online Pharmacies

Market Breakup by End Use

- Hospitals and Clinics
- -□Homecare Settings
- -□Respiratory Care Centres
- Others

Market Breakup by Country

-[Brazil

- -[]Argentina
- -[Mexico
- -∏Others

Leading Players in the Latin America Respiratory Inhalers Market

The key features of the market report include partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- -∏AstraZeneca Plc
- -□Beximco Pharmaceuticals Ltd.
- -□Boehringer Ingelheim International GmbH
- -∏Cipla Ltd
- -∏GSK Plc
- Noninklijke Philips NV
- OMRON Corp
- -□PARI Respiratory Equipment, Inc.
- -□OPKO Health, Inc
- Teva Pharmaceutical Industries Ltd

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAOs

- What is the Latin America respiratory inhalers market forecast outlook for 2024-2032?

The Latin America respiratory inhalers market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 5.4% during the forecast period of 2024-2032 and is likely to reach a market value of USD 53.9 billion by 2032.

- What are the major factors aiding the Latin America respiratory inhalers market demand?

The rising incidence of chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) is fuelling the demand for the market.

-\|\What are the major Latin America respiratory inhalers market trends?

One of the significant trends in the market is the rising emphasis on the development of eco-friendly respiratory inhaler products. For instance, in April 2024, Mundipharma and Vectura announced plans to incorporate an environmentally friendly propellant into the reformulation of flutiform used in a pressurized metered-dose inhaler (pMDI) to reduce the product's carbon footprint.

-[]What is the market segmentation based on the product type?

Based on the product type, the market is segmented into dry powdered inhalers (multi-dose dry powder inhalers, single dose dry powder inhalers), metered dose inhalers (pressured metered dose inhalers, connected metered dose inhalers), and nebulizers (compressed air nebulizers, mesh air nebulizers, ultrasonic air nebulizers), among others.

-□What is the market breakup by technology?

By technology, the market is divided into manually operated inhalers and digitally operated inhalers.

- What is the market breakup by indication?

By indication, the market includes asthma, COPD, and pulmonary arterial hypertension, among other respiratory diseases.

-□What is the market breakup by end use?

By end use, the market is segmented into hospitals and clinics, homecare settings, respiratory care centers and others.

- What are the distribution channels of the market?

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Major distribution channels of the market include hospital pharmacies, retail pharmacies and online pharmacies.

- What is the market segmentation by countries?

The market segmentation by countries includes Brazil, Argentina, and Mexico, among others.

-[]Who are the key players involved in the Latin America respiratory inhalers market?

The key players in the market are AstraZeneca Plc, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, Cipla Ltd, GSK Plc, Koninklijke Philips NV, OMRON Corp, PARI Respiratory Equipment, Inc., OPKO Health, Inc., and Teva Pharmaceutical Industries Ltd.

Meta description

The Latin America respiratory inhalers market is poised for growth, driven by the expansion of the global market, which was valued at USD 33.5 billion in 2023 and is projected to grow at a CAGR of 5.4% during the forecast period of 2024-2032.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Latin America Respiratory Inhalers Market Overview
 - 3.1 Latin America Respiratory Inhalers Market Historical Value (2017-2023)
 - 3.2 Latin America Respiratory Inhalers Market Forecast Value (2024-2032)
- 4 Latin America Respiratory Inhalers Market Landscape*
 - 4.1 Latin America Respiratory Inhalers Market: Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Latin America Respiratory Inhalers Market: Product Landscape
 - 4.2.1 Analysis by Product
 - 4.2.2 Analysis by Material
 - 4.2.3 Analysis by Type
- 5 Latin America Respiratory Inhalers Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.2.1 Strengths
 - 5.2.2 Weaknesses
 - 5.2.3 Opportunities
 - 5.2.4 Threats
 - 5.3 Porter's Five Forces Analysis
 - 5.3.1 Bargaining Power of Suppliers
 - 5.3.2 Bargaining Power of Buyers
 - 5.3.3 Threat of New Entrants
 - 5.3.4 Threat of Substitutes
 - 5.3.5 Degree of Rivalry
 - 5.4 Key Demand Indicators
 - 5.5 Key Price Indicators

- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Latin America Respiratory Inhalers Market Segmentation (2017-2032)
 - 6.1 Latin America Respiratory Inhalers Market (2017-2032) by Product Type
 - 6.1.1 Market Overview
 - 6.1.2 Dry Powdered Inhalers
 - 6.1.2.1 Multi-Dose Dry Powder Inhalers
 - 6.1.2.2 Single Dose Dry Powder Inhalers
 - 6.1.3 Metered Dose Inhalers
 - 6.1.3.1 Pressured Metered Dose Inhalers
 - 6.1.3.2 Connected Metered Dose Inhalers
 - 6.1.4 Nebulizers
 - 6.1.4.1 Compressed Air Nebulizers
 - 6.1.4.2 Mesh Air Nebulizers
 - 6.1.4.3 Ultrasonic Air Nebulizers
 - 6.1.5 Others
 - 6.2 Latin America Respiratory Inhalers Market (2017-2032) by Technology
 - 6.2.1 Market Overview
 - 6.2.2 Manually Operated Inhaler
 - 6.2.3 Digitally Operated Inhaler
 - 6.3 Latin America Respiratory Inhalers Market (2017-2032) by Indication
 - 6.3.1 Market Overview
 - 6.3.2 Asthma
 - 6.3.3 COPD
 - 6.3.4 Pulmonary Arterial Hypertension
 - 6.3.5 Other Respiratory Diseases
 - 6.4 Latin America Respiratory Inhalers Market (2017-2032) by Distribution Channel
 - 6.4.1 Market Overview
 - 6.4.2 Hospital Pharmacies
 - 6.4.3 Retail Pharmacies
 - 6.4.4 Online Pharmacies
 - 6.5 Latin America Respiratory Inhalers Market (2017-2032) by End Use
 - 6.5.1 Market Overview
 - 6.5.2 Hospitals & Clinics
 - 6.5.3 Homecare Settings
 - 6.5.4 Respiratory Care Centers
 - 6.5.5 Others
 - 6.6 Latin America Respiratory Inhalers Market (2017-2032) by Countries
 - 6.6.1 Market Overview
 - 6.6.2 Brazil
 - 6.6.3 Argentina
 - 6.6.4 Mexico
 - 6.6.5 Others
- 7 Brazil Respiratory Inhalers Market (2017-2032)
 - 7.1 Brazil Respiratory Inhalers Market (2017-2032) by Product Type
 - 7.1.1 Market Overview
 - 7.1.2 Dry Powdered Inhalers

Scotts International. EU Vat number: PL 6772247784

- 7.1.2.1 Multi-Dose Dry Powder Inhalers
- 7.1.2.2 Single Dose Dry Powder Inhalers
- 7.1.3 Metered Dose Inhalers
 - 7.1.3.1 Pressured Metered Dose Inhalers
 - 7.1.3.2 Connected Metered Dose Inhalers
- 7.1.4 Nebulizers
 - 7.1.4.1 Compressed Air Nebulizers
 - 7.1.4.2 Mesh Air Nebulizers
 - 7.1.4.3 Ultrasonic Air Nebulizers
- 7.1.5 Others
- 7.2 Brazil Respiratory Inhalers Market (2017-2032) by Technology
 - 7.2.1 Market Overview
 - 7.2.2 Manually Operated Inhaler
 - 7.2.3 Digitally Operated Inhaler
- 7.3 Brazil Respiratory Inhalers Market (2017-2032) by Indication
 - 7.3.1 Market Overview
 - 7.3.2 Asthma
 - 7.3.3 COPD
 - 7.3.4 Pulmonary Arterial Hypertension
 - 7.3.5 Other Respiratory Diseases
- 7.4 Brazil Respiratory Inhalers Market (2017-2032) by Distribution Channel
 - 7.4.1 Market Overview
 - 7.4.2 Hospital Pharmacies
 - 7.4.3 Retail Pharmacies
 - 7.4.4 Online Pharmacies
- 7.5 Brazil Inhalers Market (2017-2032) by End Use
 - 7.5.1 Market Overview
 - 7.5.2 Hospitals & Clinics
 - 7.5.3 Homecare Settings
 - 7.5.4 Respiratory Care Centers
 - 7.5.5 Others
- 8 Argentina Respiratory Inhalers Market (2017-2032)
 - 8.1 Argentina Respiratory Inhalers Market (2017-2032) by Product Type
 - 8.1.1 Market Overview
 - 8.1.2 Dry Powdered Inhalers
 - 8.1.2.1 Multi-Dose Dry Powder Inhalers
 - 8.1.2.2 Single Dose Dry Powder Inhalers
 - 8.1.3 Metered Dose Inhalers
 - 8.1.3.1 Pressured Metered Dose Inhalers
 - 8.1.3.2 Connected Metered Dose Inhalers
 - 8.1.4 Nebulizers
 - 8.1.4.1 Compressed Air Nebulizers
 - 8.1.4.2 Mesh Air Nebulizers
 - 8.1.4.3 Ultrasonic Air Nebulizers
 - 8.1.5 Others
 - 8.2 Argentina Respiratory Inhalers Market (2017-2032) by Technology
 - 8.2.1 Market Overview

Scotts International. EU Vat number: PL 6772247784

- 8.2.2 Manually Operated Inhaler
- 8.2.3 Digitally Operated Inhaler
- 8.3 Argentina Respiratory Inhalers Market (2017-2032) by Indication
 - 8.3.1 Market Overview
 - 8.3.2 Asthma
 - 8.3.3 COPD
 - 8.3.4 Pulmonary Arterial Hypertension
 - 8.3.5 Other Respiratory Diseases
- 8.4 Argentina Respiratory Inhalers Market (2017-2032) by Distribution Channel
 - 8.4.1 Market Overview
 - 8.4.2 Hospital Pharmacies
 - 8.4.3 Retail Pharmacies
 - 8.4.4 Online Pharmacies
- 8.5 Argentina Respiratory Inhalers Market (2017-2032) by End Use
 - 8.5.1 Market Overview
 - 8.5.2 Hospitals & Clinics
 - 8.5.3 Homecare Settings
 - 8.5.4 Respiratory Care Centers
 - 8.5.5 Others
- 9 Mexico Respiratory Inhalers Market (2017-2032)
 - 9.1 Mexico Respiratory Inhalers Market (2017-2032) by Product Type
 - 9.1.1 Market Overview
 - 9.1.2 Dry Powdered Inhalers
 - 9.1.2.1 Multi-Dose Dry Powder Inhalers
 - 9.1.2.2 Single Dose Dry Powder Inhalers
 - 9.1.3 Metered Dose Inhalers
 - 9.1.3.1 Pressured Metered Dose Inhalers
 - 9.1.3.2 Connected Metered Dose Inhalers
 - 9.1.4 Nebulizers
 - 9.1.4.1 Compressed Air Nebulizers
 - 9.1.4.2 Mesh Air Nebulizers
 - 9.1.4.3 Ultrasonic Air Nebulizers
 - 9.1.5 Others
 - 9.2 Mexico Respiratory Inhalers Market (2017-2032) by Technology
 - 9.2.1 Market Overview
 - 9.2.2 Manually Operated Inhaler
 - 9.2.3 Digitally Operated Inhaler
 - 9.3 Mexico Respiratory Inhalers Market (2017-2032) by Indication
 - 9.3.1 Market Overview
 - 9.3.2 Asthma
 - 9.3.3 COPD
 - 9.3.4 Pulmonary Arterial Hypertension
 - 9.3.5 Other Respiratory Diseases
 - 9.4 Mexico Respiratory Inhalers Market (2017-2032) by Distribution Channel
 - 9.4.1 Market Overview
 - 9.4.2 Hospital Pharmacies
 - 9.4.3 Retail Pharmacies

Scotts International. EU Vat number: PL 6772247784

9.4.4 Online Pharmacies

- 9.5 Mexico Respiratory Inhalers Market (2017-2032) by End Use
 - 9.5.1 Market Overview
 - 9.5.2 Hospitals & Clinics
 - 9.5.3 Homecare Settings
 - 9.5.4 Respiratory Care Centers
 - 9.5.5 Others
- 10 Regulatory Framework
- 11 Partnership and Collaborations Analysis
 - 11.1 Analysis by Partnership Instances
 - 11.2 Analysis by Type of Partnership
 - 11.3 Analysis by Leading Players
 - 11.4 Analysis by Geography
- 12 Supplier Landscape
 - 12.1 Market Share by Top 5 Companies
 - 12.2 AstraZeneca Plc
 - 12.2.1 Financial Analysis
 - 12.2.2 Product Portfolio
 - 12.2.3 Demographic Reach and Achievements
 - 12.2.4 Mergers and Acquisitions
 - 12.2.5 Certifications
 - 12.3 Beximco Pharmaceuticals Ltd.
 - 12.3.1 Financial Analysis
 - 12.3.2 Product Portfolio
 - 12.3.3 Demographic Reach and Achievements
 - 12.3.4 Mergers and Acquisitions
 - 12.3.5 Certifications
 - 12.4 Boehringer Ingelheim International GmbH
 - 12.4.1 Financial Analysis
 - 12.4.2 Product Portfolio
 - 12.4.3 Demographic Reach and Achievements
 - 12.4.4 Mergers and Acquisitions
 - 12.4.5 Certifications
 - 12.5 Cipla Ltd
 - 12.5.1 Financial Analysis
 - 12.5.2 Product Portfolio
 - 12.5.3 Demographic Reach and Achievements
 - 12.5.4 Mergers and Acquisitions
 - 12.5.5 Certifications
 - 12.6 GSK Plc
 - 12.6.1 Financial Analysis
 - 12.6.2 Product Portfolio
 - 12.6.3 Demographic Reach and Achievements
 - 12.6.4 Mergers and Acquisitions
 - 12.6.5 Certifications
 - 12.7 Koninklijke Philips NV
 - 12.7.1 Financial Analysis

Scotts International. EU Vat number: PL 6772247784

- 12.7.2 Product Portfolio
- 12.7.3 Demographic Reach and Achievements
- 12.7.4 Mergers and Acquisitions
- 12.7.5 Certifications
- 12.8 OMRON Corp
 - 12.8.1 Financial Analysis
 - 12.8.2 Product Portfolio
 - 12.8.3 Demographic Reach and Achievements
 - 12.8.4 Mergers and Acquisitions
 - 12.8.5 Certifications
- 12.9 PARI Respiratory Equipment, In
 - 12.9.1 Financial Analysis
 - 12.9.2 Product Portfolio
 - 12.9.3 Demographic Reach and Achievements
 - 12.9.4 Mergers and Acquisitions
 - 12.9.5 Certifications
- 12.10 OPKO Health, Inc
 - 12.10.1 Financial Analysis
 - 12.10.2 Product Portfolio
 - 12.10.3 Demographic Reach and Achievements
 - 12.10.4 Mergers and Acquisitions
 - 12.10.5 Certifications
- 12.11 Teva Pharmaceutical Industries Ltd
 - 12.11.1 Financial Analysis
 - 12.11.2 Product Portfolio
 - 12.11.3 Demographic Reach and Achievements
 - 12.11.4 Mergers and Acquisitions
 - 12.11.5 Certifications
- 13 Latin America Respiratory Inhalers Market Distribution Model (Additional Insight)
 - 13.1 Overview
 - 13.2 Potential Distributors
 - 13.3 Key Parameters for Distribution Partner Assessment
- 14 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 15 Company Competitiveness Analysis (Additional Insight)
 - 15.1 Very Small Companies
 - 15.2 Small Companies
 - 15.3 Mid-Sized Companies
 - 15.4 Large Companies
 - 15.5 Very Large Companies
- 16 Payment Methods (Additional Insight)
 - 16.1 Government Funded
 - 16.2 Private Insurance
 - 16.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Print this form

To place an Order with Scotts International:

Latin America Respiratory Inhalers Market Report and Forecast 2024-2032

Market Report | 2024-06-26 | 140 pages | EMR Inc.

☐ - Complete the re	evant blank fields and sign			
 Send as a scanned email to support@scotts-international.com 				
ORDER FORM:				
Select license	License			Price
	Single User License			\$3999.00
	Five User License			\$5299.00
	Corporate License			\$6299.00
			VAT	
			Total	
Email*	23% for Polish based companies, individu	Phone*	panies who are unable to provide a	valid EO vat Number
First Name*		Last Name*		
Job title*				
Company Name*		EU Vat / Tax ID / NII	P number*	
Address*		City*		
Zip Code*		Country*		
		Date	2025-05-05	
		Signature		

Scotts International. EU Vat number: PL 6772247784